Abstract: Under the context of much disadvantages, including lack of brands, governmental protection and market prioritity, a few local pharmaceutical manufacturing companies in China become the main actors of R&D and innovative activities gradually in pharmaceutical manufacturing industry. In order to survive and develop well, these companies have achieved successfully from generic drug of totally low end to become the first enterprise to introduce generic drugs in China, and ME-TOO drugs, at last ,these companies launched innovative drugs of national or even world-class, therefore, their innovation performance have been improved ultimately. Using a multiple case study, this paper explores the impact of R&D partners diversity of the focal firm on innovation performance and the impact of strategic orientation on R&D partners diversity.

摘要： 我国少数本土医药制造企业在没有品牌、缺乏政府保护和市场优先权的劣势下逐渐成为医药制造行业中研发与创新活动的主体，它们为了生存和发展，通过选择合作伙伴共同开展研发活动，成功实现了从完全模仿的低端仿制药到首仿药和ME-TOO药开发、最后自主创新地推出国家级甚至国际级创新药物，最终实现了创新绩效的提升。那么，在这类企业的研发活动中，其伙伴的多样性是如何影响企业的创新绩效呢？文章通过对3家医药制造企业的多案例分析，探索了企业的研发伙伴多样性是否以及如何影响其创新绩效，同时，还探讨了影响研发伙伴多样性的前置因素，即战略导向的作用。